Why Is AIM ImmunoTech Stock (AIM) Up Today?

AIM ImmunoTech AIM +80.28% ▲ stock underwent a massive rally on Wednesday after the immuno-pharma company received final approval for its novel cancer therapy in Japan. The Japanese Patent Office has approved the company’s patent that combines Ampligen with checkpoint inhibitors for the treatment of cancer.

Claim 70% Off TipRanks Premium

• Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions

• Stay ahead of the market with the latest news and analysis and maximize your portfolio’s potential

AIM ImmunoTech noted that the patent is wide and covers multiple forms of cancer. That includes pancreatic cancer, which is expected to see a significant increase in the U.S. and Japan by 2030. Investors will also note that AIM ImmunoTech holds a similar patent in the U.S. to treat cancer with a combination of Ampligen and checkpoint inhibitors. The company also intends to expand its intellectual property portfolio in Japan by submitting Ampligen for orphan drug designation.

AIM ImmunoTech CEO Thomas Equels stated, “AIM is committed to developing Ampligen for the treatment of late-stage pancreatic cancer, which is an extremely lethal and unmet global health problem. Securing this critical patent in a key global market is just the latest step in AIM’s robust development and commercialization strategy.”

AIM ImmunoTech Stock Rallies Today

AIM ImmunoTech stock was up 97.18% on Wednesday, building on a 24.11% rally year-to-date. Even so, the stock was still down 94.21% over the past 12 months.

With today’s news came increased trading activity for AIM stock, as some 10.6 million shares changed hands, compared to a three-month average daily trading volume of about 2.7 million shares.

Is AIM ImmunoTech Stock a Buy, Sell, or Hold?

Turning to Wall Street, traditional analyst coverage of AIM ImmunoTech is lacking. Fortunately, TipRanks’ AI analyst Spark has it covered. Spark rates AIM stock as Underperform with a $1.50 price target. It cites “very weak financial performance (large losses, negative equity, and ongoing cash burn)” as reasons for this stance.

Disclaimer & DisclosureReport an Issue